{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:34:39Z","timestamp":1787164479181,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the advent of innovative therapies including biologics and Janus kinase inhibitors, children with rheumatic diseases are more likely to have improved outcomes. Despite these advances, some children do not respond, or they, or their parents fear adverse events and seek other alternatives. Increasingly, private companies are offering mesenchymal stem cells (MSC) as an alternative, which are described as natural therapies for rheumatic diseases, often insinuating them as a cure. MSC have immunomodulatory properties, and transplantation of these stem cells have been used to successfully treat immunologic conditions like graft-versus-host disease. Lately, MSC research in adult lupus has been encouraging, but the clinical trials are still underway and in most, MSC therapy is not a standalone treatment. This retrospective case series will highlight three cases of pediatric refractory autoimmune disease whose parents sought out and received MSC therapy as a self-decision without first seeking medical advice from our specialty. The three families felt that their children were improved and in two believed that their child was cured. MSC have the potential of beneficial immunomodulation and may be a powerful tool in the therapy of rheumatic disease, but well controlled clinical trials are necessary and should be designed and monitored by experts in childhood rheumatic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Three children with three different rheumatic diseases; systemic lupus erythematosus, mixed connective tissue disease and juvenile idiopathic arthritis were under the care of pediatric rheumatology at a large, tertiary-care, teaching institution. Multiple non-biologic and biologic disease-modifying anti-rheumatic drugs failed to significantly decrease disease activity, and as a result, the families chose to undergo MSC therapy. After transplantation, all children improved per patient and parent report and tapered off conventional immunosuppressive drugs. No serious adverse events occurred in these three patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The three cases presented in this report reflect comparable beneficial outcomes and minimal risks published in adult studies. These were not controlled studies, however, and benefit was reported rather than documented. These cases suggest that MSC transplantation may prove a promising adjunctive treatment option; however, further research, development of standardized infusion therapy protocols, and well-designed monitored clinical trials are essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-021-00575-5","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T15:08:02Z","timestamp":1623337682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Uncharted waters: mesenchymal stem cell treatment for pediatric refractory rheumatic diseases; a single center case series"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1617-9634","authenticated-orcid":false,"given":"Stephen C.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah C.","family":"Medrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice D.","family":"Hoftman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olcay Y.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"issue":"4","key":"575_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3904\/kjim.2013.28.4.387","volume":"28","author":"N Kim","year":"2013","unstructured":"Kim N, Cho S. Clinical applications of mesenchymal stem cells. Korean J Intern Med. 2013;28(4):387\u2013402. https:\/\/doi.org\/10.3904\/kjim.2013.28.4.387.","journal-title":"Korean J Intern Med"},{"issue":"10","key":"575_CR2","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1182\/blood.V99.10.3838","volume":"99","author":"M Di Nicola","year":"2002","unstructured":"Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838\u201343. https:\/\/doi.org\/10.1182\/blood.V99.10.3838.","journal-title":"Blood."},{"issue":"3","key":"575_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2007-02-074997","volume":"111","author":"GM Spaggiari","year":"2008","unstructured":"Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111(3):1327\u201333. https:\/\/doi.org\/10.1182\/blood-2007-02-074997.","journal-title":"Blood."},{"issue":"1","key":"575_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","volume":"107","author":"A Corcione","year":"2006","unstructured":"Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367\u201372. https:\/\/doi.org\/10.1182\/blood-2005-07-2657.","journal-title":"Blood."},{"issue":"9","key":"575_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/molehr\/gau044","volume":"20","author":"S Nikoo","year":"2014","unstructured":"Nikoo S, Ebtekar M, Jeddi-Tehrani M, Shervin A, Bozorgmehr M, Vafaei S, et al. Menstrual blood-derived stromal stem cells from women with and without endometriosis reveal different phenotypic and functional characteristics. Mol Hum Reprod. 2014;20(9):905\u201318. https:\/\/doi.org\/10.1093\/molehr\/gau044.","journal-title":"Mol Hum Reprod"},{"issue":"8","key":"575_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/ard.2009.123463","volume":"69","author":"J Liang","year":"2010","unstructured":"Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010;69(8):1423\u20139. https:\/\/doi.org\/10.1136\/ard.2009.123463.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"575_CR7","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/art.27548","volume":"62","author":"L Sun","year":"2010","unstructured":"Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2467\u201375. https:\/\/doi.org\/10.1002\/art.27548.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"575_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nrrheum.2010.80","volume":"6","author":"J Liang","year":"2010","unstructured":"Liang J, Gu F, Wang H, Hua B, Hou Y, Shi S, et al. Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE. Nat Rev Rheumatol. 2010;6(8):486\u20139. https:\/\/doi.org\/10.1038\/nrrheum.2010.80.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"575_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s12015-020-09954-z","volume":"16","author":"A Karamini","year":"2020","unstructured":"Karamini A, Bakopoulou A, Andreadis D, Gkiouras K, Kritis A. Therapeutic potential of Mesenchymal stromal stem cells in rheumatoid arthritis: a systematic review of in vivo studies. Stem Cell Rev Rep. 2020;16(2):276\u201387. https:\/\/doi.org\/10.1007\/s12015-020-09954-z PMID: 31950339.","journal-title":"Stem Cell Rev Rep"},{"issue":"10","key":"575_CR10","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1093\/rheumatology\/kez157","volume":"58","author":"JF Swart","year":"2019","unstructured":"Swart JF, de Roock S, Nievelstein RAJ, Slaper-Cortenbach ICM, Boelens JJ, Wulffraat NM. Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients. Rheumatology. 2019;58(10):1812\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kez157.","journal-title":"Rheumatology"},{"key":"575_CR11","doi-asserted-by":"publisher","first-page":"9165267","DOI":"10.1155\/2016\/9165267","volume":"2016","author":"L Wang","year":"2016","unstructured":"Wang L, Zhang Y, Li H, Hong J, Chen X, Li M, et al. Clinical observation of employment of umbilical cord derived Mesenchymal stem cell for juvenile idiopathic arthritis therapy. Stem Cells Int. 2016;2016:9165267. https:\/\/doi.org\/10.1155\/2016\/9165267 Epub 2015 Dec 6. PMID: 26770214; PMCID: PMC4684881.","journal-title":"Stem Cells Int"},{"key":"575_CR12","first-page":"1","volume":"40","author":"J Cohnheim","year":"1867","unstructured":"Cohnheim J. Ueber Entz\u00fcndung und Eiterung. Archiv Pathologische Anatomie Physiologie Klinische Medicin. 1867;40:1\u201379.","journal-title":"Archiv Pathologische Anatomie Physiologie Klinische Medicin"},{"issue":"4","key":"575_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00007890-197404000-00001","volume":"17","author":"AJ Friedenstein","year":"1974","unstructured":"Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17(4):331\u201340. https:\/\/doi.org\/10.1097\/00007890-197404000-00001.","journal-title":"Transplantation."},{"issue":"5","key":"575_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jor.1100090504","volume":"9","author":"AI Caplan","year":"1991","unstructured":"Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641\u201350. https:\/\/doi.org\/10.1002\/jor.1100090504.","journal-title":"J Orthop Res"},{"issue":"3","key":"575_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.stem.2008.07.003","volume":"3","author":"M Crisan","year":"2008","unstructured":"Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3(3):301\u201313. https:\/\/doi.org\/10.1016\/j.stem.2008.07.003.","journal-title":"Cell Stem Cell"},{"issue":"8","key":"575_CR16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1089\/scd.2011.0200","volume":"21","author":"M Corselli","year":"2012","unstructured":"Corselli M, Chen CW, Sun B, Yap S, Rubin JP, Peault B. The tunica adventitia of human arteries and veins as a source of mesenchymal stem cells. Stem Cells Dev. 2012;21(8):1299\u2013308. https:\/\/doi.org\/10.1089\/scd.2011.0200.","journal-title":"Stem Cells Dev"},{"key":"575_CR17","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jcyt.2019.04.003","volume":"21","author":"DG Phinney","year":"2019","unstructured":"Phinney DG, et al. Manufacturing mesenchymal stromal cells for clinical applications: a survey of good manufacturing practices at U.S. academic centers. Cytotherapy. 2019;21:782\u201392.","journal-title":"Cytotherapy"},{"issue":"6","key":"575_CR18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824\u201333. https:\/\/doi.org\/10.1016\/j.stem.2018.05.004.","journal-title":"Cell Stem Cell"},{"key":"575_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6518508","volume":"2020","author":"T Zhou","year":"2020","unstructured":"Zhou T, Li HY, Liao C, Lin W, Lin S. Clinical efficacy and safety of Mesenchymal stem cells for systemic lupus Erythematosus. Stem Cells Int. 2020;2020:1\u201311. https:\/\/doi.org\/10.1155\/2020\/6518508.","journal-title":"Stem Cells Int"},{"issue":"1","key":"575_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000496809","volume":"46","author":"S Elgaz","year":"2019","unstructured":"Elgaz S, Ku\u00e7i Z, Ku\u00e7i S, B\u00f6nig H, Bader P. Clinical use of Mesenchymal stromal cells in the treatment of acute graft-versus-host disease. Transfus Med Hemother. 2019;46(1):27\u201334. https:\/\/doi.org\/10.1159\/000496809.","journal-title":"Transfus Med Hemother"},{"key":"575_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/3618217","volume":"2019","author":"MB Avery","year":"2019","unstructured":"Avery MB, Belanger BL, Bromley A, Sen A, Mitha AP. Mesenchymal stem cells exhibit both a Proinflammatory and anti-inflammatory effect on Saccular aneurysm formation in a rabbit model. Stem Cells Int. 2019;2019:1\u201315. https:\/\/doi.org\/10.1155\/2019\/3618217.","journal-title":"Stem Cells Int"},{"key":"575_CR22","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/j.1600-6143.2012.04115","volume":"12","author":"F Casiraghi","year":"2012","unstructured":"Casiraghi F, Azzollini N, Todeschini M, Cavinato RA, Cassis P, Solini S, et al. Localization of Mesenchymal stromal cells dictates their immune or Proinflammatory effects in kidney transplantation. Am J Transplant. 2012;12:2373\u201383. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04115.","journal-title":"Am J Transplant"},{"key":"575_CR23","doi-asserted-by":"publisher","unstructured":"Kanematsu Y, Kanematsu M, Kurihara C, et al. Critical roles of macrophages in the formation of intracranial aneurysm. Stroke. 2011;42(1):173\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.110.590976.","DOI":"10.1161\/STROKEAHA.110.590976"},{"issue":"5","key":"575_CR24","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.stem.2012.03.007","volume":"10","author":"K Akiyama","year":"2012","unstructured":"Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand\u2212\/FAS-mediated T cell apoptosis. Cell Stem Cell. 2012;10(5):544\u201355. https:\/\/doi.org\/10.1016\/j.stem.2012.03.007.","journal-title":"Cell Stem Cell"},{"issue":"20","key":"575_CR25","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.111.036061","volume":"124","author":"BL Hoh","year":"2011","unstructured":"Hoh BL, Hosaka K, Downes DP, et al. Monocyte chemotactic Protein-1 promotes inflammatory vascular repair of murine carotid aneurysms via a macrophage inflammatory protein-1\u03b1 and macrophage inflammatory Protein-2\u2013dependent pathway. Circulation. 2011;124(20):2243\u201352.","journal-title":"Circulation"},{"issue":"3","key":"575_CR26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.athoracsur.2009.02.093","volume":"88","author":"AM Abarbanell","year":"2009","unstructured":"Abarbanell AM, Coffey AC, Fehrenbacher JW, Beckman DJ, Herrmann JL, Weil B, et al. Proinflammatory cytokine effects on mesenchymal stem cell therapy for the ischemic heart. Ann Thorac Surg. 2009;88(3):1036\u201343.","journal-title":"Ann Thorac Surg"},{"issue":"10","key":"575_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047559","volume":"7","author":"MM Lalu","year":"2012","unstructured":"Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with Mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. https:\/\/doi.org\/10.1371\/journal.pone.0047559.","journal-title":"PLoS One"},{"key":"575_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fcell.2019.00285","volume":"7","author":"R-J Cheng","year":"2019","unstructured":"Cheng R-J, Xiong A-J, Li Y-H, Pan S-Y, Zhang Q-P, Zhao Y, et al. Marion TN Mesenchymal stem cells: allogeneic MSC may be immunosuppressive but autologous MSC are dysfunctional in lupus patients. Front Cell Dev Biol. 2019;7:285. https:\/\/doi.org\/10.3389\/fcell.2019.00285.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"575_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/1479-5876-9-181","volume":"9","author":"JC Ra","year":"2011","unstructured":"Ra JC, Kang SK, Shin IS, Park HG, Joo SA, Kim JG, et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med. 2011;9(1):181. https:\/\/doi.org\/10.1186\/1479-5876-9-181.","journal-title":"J Transl Med"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00575-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00575-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00575-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T15:09:17Z","timestamp":1623337757000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00575-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00575-5","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"27 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"University of California Los Angeles Institutional Review Board waived the requirement of ethics and consent approval due to nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Verbal and written consent for publication was obtained from the patient, or in the case of children, their parent or legal guardian. All clinics and companies mentioned consented to being named in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SW, LM, AH, OYJ, DM - The authors declare that they have no competing interests or financial relationships relevant to this article to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}